Search
1st joint EHA – Balkan Hematology Day, a meeting of true regional commitment
1st joint EHA – Balkan Hematology Day
Friday, October 11, 2019 | Pravets, Bulgaria
Meeting Chairs:
Prof Gert Ossenkoppele, Chair EHA Education Committee
Prof Gianluca Gaidano, Chair EHA Global Outreach Program Unit
Prof Margarita Guenova, Representative Balkan Societies
On Friday, October 11th the European Hematology Association (EHA)…
Press Release: Better funding for research into blood diseases will save more lives
“Haematology is probably the area of medicine that has progressed the most in recent years”, said Professor Robin Foà of “La Sapienza” University of Rome.
Read moreEHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023
On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.
Read moreEHA Statement: Our sustained solidarity with the hematology community in Ukraine
Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.
Read moreEHA endorses the International COVID-19 Blood Cancer Coalition (ICBCC) Statement
On February 21, the COVID-19 Blood Cancer Coalition (ICBCC), a multi-stakeholder coalition including representatives from the global patient advocacy and clinical community, launched its Joint Patient Impact Statement and Recommendations for protecting immunocompromised blood cancer patients during the COVID-19 pandemic.
Read moreProfessor Degos awarded at the 17th Congress of EHA in Amsterdam
Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.
Read moreJosé Carreras Award handed out at the 17th Congress of EHA
He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- »